Business
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"text","content":"RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment.\n\n \n \n \n \n \n \n\n \nTony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of development and commercialization.\n\"I am pleased to announce Tony's appointment to the Indivior Board. He is an experienced biopharmaceutical leader recognized for his strategic vision, operational expertise, and ability to drive growth in complex, regulated environments,\" said David Wheadon, M.D., Chair of the Board of Indivior. \"Tony's significant commercial and clinical development experience will be invaluable to Indivior as we work to realize the full potential of SUBLOCADE® and deliver value to all Indivior stakeholders.\"\n\"Indivior has a long and successful track record of addressing the opioid use disorder with its portfolio of medicines to make meaningful recovery possible,\" said Mr. Kingsley. \"I look forward to working closely with the Board and management team to advance Indivior's mission and strengthen its position as a leader in delivering life-transforming treatments for opioid use disorder.\"\nMr. Kingsley currently serves as CEO and Director of Stablix, Inc., a biotechnology company pioneering deubiquitination therapeutics as novel modality. Prior to joining Stablix, Mr. Kingsley was President and CEO of Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases driven by protein growth factors. Previously, he led TARIS Bio as President and CEO, guiding the company through its acquisition by Janssen Pharmaceuticals in 2019. Earlier in his career, Mr. Kingsley held a series of senior leadership roles, including President and Chief Operating Officer at The Medicines Company and Executive Vice President of Global Commercial Operations at Biogen, where he oversaw the launch and growth of multiple therapies in neurology and hemophilia. Prior to this, he held numerous se...